176 citations
,
September 2006 in “Stem Cells” BMP signaling prevents hair growth by stopping stem cell activation.
4 citations
,
October 2018 in “International Braz J Urol” Taking 5-alpha reductase inhibitors does not increase the risk of breast cancer in men.
January 2024 in “Research Square (Research Square)” The research identified genes linked to male-pattern baldness and potential drug targets for treatment.
April 2023 in “Dermatology practical & conceptual” Tacrolimus solution is effective and well-tolerated for treating inflammatory scalp conditions.
18 citations
,
August 2021 in “PLoS ONE” Melanocyte progenitor cells are found in human fat tissue and can become mature melanocytes, which may help treat skin issues.
October 2020 in “Plastic Surgery” Bone marrow stem cells improve healing of deep skin wounds.
40 citations
,
November 2017 in “International journal of nanomedicine” DA liposomes with chloramphenicol effectively target hair follicles and combat MRSA with minimal skin toxicity.
May 2015 in “Journal of The American Academy of Dermatology” Both treatments help with hair regrowth in alopecia areata, but azathioprine has milder side effects than betamethasone.
January 2018 in “프로그램북(구 초록집)” Botulinum toxin type A is a safe and effective treatment for male pattern baldness.
June 2018 in “Dermatologic Surgery”
Photobiomodulation improves the quality of life for people with hair loss.
7 citations
,
October 2017 in “Urologic Oncology: Seminars and Original Investigations” Men with male pattern baldness have a higher risk of aggressive prostate cancer and benign prostatic hyperplasia.
January 2024 in “Aesthetic Plastic Surgery” Botox can help prevent hair loss by blocking cell death in scalp cells.
1 citations
,
June 2023 in “Pharmacognosy Research” Bacopa monnieri, or Brahmi, is a traditional herb that may improve memory and treat various conditions, but more research is needed.
September 2024 in “Journal of the American Academy of Dermatology” The compounded topical solution is safe, stable, and effective for personalized alopecia treatment.
37 citations
,
August 2016 in “Clinical, Cosmetic and Investigational Dermatology” The document concludes that better treatments for CCCA are needed and more research is required to understand its causes related to hairstyling and genetics.
13 citations
,
September 2011 in “American Journal of Clinical Dermatology” The oral contraceptive ethinylestradiol/chlormadinone acetate is effective in reducing acne and improving other skin conditions related to high androgen levels.
September 2023 in “Journal of The American Academy of Dermatology” The document's conclusion cannot be provided because the content is not available.
June 2023 in “Zenodo (CERN European Organization for Nuclear Research)” April 2020 in “Journal of the Endocrine Society” Type 3 acromegaly patients have more health issues and higher death risk.
July 2022 in “Journal of Cosmetic Dermatology” Isotretinoin with tacrolimus may be more effective short-term for treating frontal fibrosing alopecia than finasteride with tacrolimus.
January 2025 in “JCEM Case Reports” Metyrapone can effectively treat Cushing's Disease even if the mass causing it is not found.
15 citations
,
February 2003 in “British Journal of Dermatology” The study suggests computer-assisted analysis of scalp biopsies could improve hair loss diagnosis but needs more validation.
March 2026 in “Preprints.org” The MIRA technique improves cellulite treatment results and patient satisfaction.
15 citations
,
September 2018 in “Frontiers in Plant Science” BcFLA1 protein is crucial for root hair growth in response to low phosphate in Brassica carinata.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib shows promise in improving frontal fibrosing alopecia symptoms.
Baicalin may effectively treat hair loss by inhibiting 5α-reductase.
32 citations
,
July 2017 in “Wiley Interdisciplinary Reviews-Developmental Biology” Transit-amplifying cells are crucial for tissue repair and can contribute to cancer when they malfunction.
September 2023 in “Journal of The American Academy of Dermatology” Reducing the dose of Baricitinib to 2mg led to a loss of hair regrowth benefits in nearly half of the patients by Week-104.